Myasthenia Gravis

August 28th 2025

Efgartigimod shows promise as a groundbreaking treatment for seronegative generalized myasthenia gravis (gMG), addressing a critical unmet need in patient care.

August 25th 2025

Using US claims data, the authors evaluated oral glucocorticoid (GC) use at 5 time points during their retrospective analysis: 3 months before starting efgartigimod and 3, 6, 9, and 12 months after starting efgartigimod.

August 22nd 2025

The humanized IgG4 monoclonal antibody was first approved for myasthenia gravis in the US in 2023, with approvals in Japan and the European Union following later that year and 2025, respectively.

August 19th 2025

Despite nurses often being the first health care workers many patients encounter, they frequently lack adequate tools to optimally evaluate their patients’ conditions, as in the case with myasthenia gravis and being able to predict patients at risk of myasthenic crisis.